Creating sustainability and longevity for biosimilars



We advance access with integrated commercialization services for all biosimilars

Our relationships span:
health systems
100%
of u.s. hospitals
oncology
60%
of U.S. community oncology market
nephrology
90%
of U.S. renal market
opHthamology
4,200
provider sites
rheumatology
2,100
provider sites

Resources & Education

Read the FDA's guidance on biosimilars and get answers to patients' frequently asked questions.

Connect With an Expert

Find out more about how AmerisourceBergen can support your product or practice as the biosimilars market in the U.S. expands.
Two women speaking in an office
 

"The right conditions exist in the U.S. for biosimilar commercialization success. Competition has proven to bring prices down – look at the generics market over the last 30 years – but now we need to create a supportive system."

STEVE COLLIS, CHAIRMAN, PRESIDENT AND CEO, AMERISOURCEBERGEN 

Read more

Connect With an Expert

Sean McGowan, Sr. Director, Biosimilars at amerisourcebergen
Contact Sean